Key Trends Influencing the Growth of the Intravenous Iron Drugs Market in 2025: Focus On Intravenous Iron Replacement Therapy For Improved Patient Outcomes

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Intravenous Iron Drugs Market Through 2025?
The market for intravenous iron drugs has seen a swift expansion in its size over the last few years. The market, which was at $3.44 billion in 2024, is forecasted to reach $3.81 billion in 2025, reflecting a compound annual growth rate (CAGR) of 10.6%. The factors driving the growth during the historic period include a higher occurrence of iron deficiency anemia, increased cases of chronic illnesses, an escalation in healthcare expenditures, an aging population, and a rising number of targeted diseases.

What's the Projected Size of the Global Intravenous Iron Drugs Market by 2029?
The market size of intravenous iron drugs is anticipated to witness a significant expansion in the upcoming years, estimated to reach $5.73 billion by 2029 with a CAGR of 10.8%. This vigorous growth projected during the forecast period could be ascribed to factors such as governmental initiatives, increased research and development in the realm of IV iron drugs, rising demand for these medicines, elevated amount of R&D operations, and advancements in their administration and formulation. The forecast period is expected to introduce trends like advanced IV iron treatments, progression in drug development, a shift towards more user-friendly IV iron therapies, strategic alliances and acquisitions, and introduction of innovative drug delivery systems.

View the full report here:
https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report

Top Growth Drivers in the Intravenous Iron Drugs Industry: What's Accelerating the Market?
The increasing prevalence of Chronic Kidney Disease (CKD) is predicted to catalyze the expansion of the intravenous iron drugs market. Chronic Kidney Disease (CKD) is a condition characterized by a slow and progressive decline in kidney function, which results in the kidneys' failure to efficiently remove waste and surplus fluids from the blood. This escalating prevalence of CKD is attributed to the rising cases of diabetes and hypertension, which gradually inflict damage to the kidneys. Intravenous iron drugs serve as an important treatment option for CKD patients, as it helps restore iron levels, rectify anemia, and enhance hemoglobin levels leading to improved oxygen transport and less dependency on erythropoiesis-stimulating agents. As an example, the Australian Institute of Health and Welfare, a government agency based in Australia, reported in June 2024 that mortality rates due to Chronic Kidney Disease (CKD) increased by 4.2% in 2021 and by 6.2% in 2022. CKD was accountable for approximately 22,000 deaths in Australia in 2022, which constituted 11% of all deaths. Consequently, the escalating prevalence of Chronic Kidney Disease (CKD) is fueling the growth of the intravenous iron drugs market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp

Which Emerging Trends Are Transforming the Intravenous Iron Drugs Market in 2025?
Leading players in the intravenous iron drugs market are prioritizing the development of novel treatments such as intravenous (IV) iron replacement therapy to augment efficacy, safety, and patient results. The intravenous (IV) iron replacement therapy is a medical remedy that transmits iron right into the bloodstream through an IV infusion, addressing iron deficiency and anemia, particularly in patients who have difficulty tolerating or appropriately absorbing oral iron supplements. For example, in June 2023, Injectafer (ferric carboxymaltose injection), a product of Daiichi Sankyo Company Limited, a pharmaceutical firm based in Japan known for its unique drug development and healthcare solutions, received approval from the U.S. Food and Drug Administration (FDA) to treat iron deficiency in adult heart failure patients classified as New York Heart Association class II/III, thereby increasing their exercise capacity. Injectafer is recognized as a prevalent intravenous iron therapy that swiftly restores iron levels in patients who do not tolerate or respond positively to oral iron supplements.

What Are the Main Segments in the Intravenous Iron Drugs Market?
The intravenous iron drugs market covered in this report is segmented -

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types
2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:
1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran
2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex
3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose
4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=23430&type=smp

Which Top Companies are Driving Growth in the Intravenous Iron Drugs Market?
Major companies operating in the intravenous iron drugs market are AbbVie Inc., Sanofi S.A., Amgen Inc., Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., CSL Limited, Sandoz Group AG., Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Galenica Ltd., Dr.Reddy's Laboratories, Hikma Pharmaceuticals plc, Zydus Lifesciences Limited, Biocon Limited, Kissei Pharmaceutical Co. Ltd., American Regent Inc., Akebia Therapeutics Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Mitsubishi Tanabe Pharma Corporation

Which Regions Will Dominate the Intravenous Iron Drugs Market Through 2029?
North America was the largest region in the intravenous iron drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23430

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.